基于直线加速器的VMAT放射外科治疗多脑病灶:常规多等中心与新型单等中心技术的比较
该研究比较了HyperArc单等中心VMAT方案与常规多等中心VMAT方案治疗多脑转移瘤的剂量学及治疗效率。20例患者(平均5个病灶)接受1-3次HyperArc治疗,处方剂量单次18-25 Gy、三次21-27 Gy。结果显示HyperArc方案适形性指数更高、梯度指数更低,且机器跳数和整体治疗时间显著减少。
核心结论
- 对于基于直线加速器的多脑病灶SRS/FSRT,HyperArc方案较标准多等中心VMAT方案具有更高的适形性和更低的梯度指数。
- HyperArc治疗可在典型20分钟时间内完成,较预期多等中心VMAT治疗时间显著缩短。
研究设计与样本
- 2017年8月至10月纳入20例多脑转移瘤患者(平均5个,范围2-10个),接受HyperArc治疗1-3次。
- 处方剂量单次18-25 Gy,三次21-27 Gy;PTV由每病灶外扩2 mm等距边界定义,平均体积9.6 cm3(范围0.5-27.9 cm3)。
- HyperArc方案采用5条非共面180°弧(床角0°、±45°、±90°),与每等中心2条共面360°弧的多等中心VMAT方案进行比较。
- 剂量归一为98%PTV接受100%处方剂量,接受D2%(PTV)<150%处方剂量;所有方案需满足脑干D0.5cm3<18 Gy及视神经/视交叉、眼、晶状体D0.5cm3<15 Gy。
关键数值与推荐
- 剂量归一要求98%PTV接受100%处方剂量,D2%(PTV)<150%处方剂量。
- 脑干约束D0.5cm3<18 Gy,视神经/视交叉、眼、晶状体约束D0.5cm3<15 Gy。
- 单次处方剂量18-25 Gy,三次处方剂量21-27 Gy。
- PTV由每病灶外扩2 mm等距边界定义。
临床怎么用
- 对于多脑转移瘤的直线加速器SRS/FSRT,HyperArc单等中心方案可提供更优的适形性和剂量梯度。
- HyperArc方案可显著缩短机器跳数和整体治疗时间,有利于在典型20分钟时间内完成治疗。
- 需注意HyperArc方案在低剂量区域(低于2-5 Gy)对脑减PTV的保护可能不及多等中心方案。
局限性
- 多等中心方案的整体治疗时间系估算值,基于初始摆位3分钟加每等中心CBCT引导摆位校正5分钟的假设。
- 为单中心初始经验,样本量20例,随访时间限于2017年8月至10月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Linac-based stereotactic radiosurgery or fractionated stereotactic radiotherapy (SRS/FSRT) of multiple brain lesions using volumetric modulated arc therapy (VMAT) is typically performed by a multiple-isocenter approach, i.e. one isocenter per lesion, which is time-demanding for the need of independent setup verifications of each isocenter. Here, we present our initial experience with a new dedicated mono-isocenter technique with multiple non-coplanar arcs (HyperArc™, Varian Inc.) in terms of a plan comparison with a multiple-isocenter VMAT approach. METHODS: From August 2017 to October 2017, 20 patients with multiple brain metastases (mean 5, range 2-10) have been treated by HyperArc in 1-3 fractions. The prescribed doses (Dp) were 18-25 Gy in single-fraction, and 21-27 Gy in three-fractions. Planning Target Volume (PTV), defined by a 2 mm isotropic margin from each lesion, had mean dimension of 9.6 cm3 (range 0.5-27.9 cm3). Mono-isocenter HyperArc VMAT plans (HA) with 5 non-coplanar 180°-arcs (couch at 0°, ±45°, ±90°) were generated and compared to multiple-isocenter VMAT plans (RA) with 2 coplanar 360°-arcs per isocenter. A dose normalization of 100%Dp at 98%PTV was adopted, while D2%(PTV) < 150%Dp was accepted. All plans had to respect the constraints on maximum dose to the brainstem (D0.5cm3 < 18 Gy) as well as to the optical nerves/chiasm, eyes and lenses (D0.5cm3 < 15 Gy). HA and RA plans were compared in terms of dose-volume metrics, by Paddick conformity (CI) and gradient (GI) index and by V12 and mean dose to the brain-minus-PTV, and in terms of MU and overall treatment time (OTT) per fraction. OTT was measured for HA treatments, whereas for RA plans OTT was estimated by assuming 3 min. For initial patient setup plus 5 min. For each CBCT-guided setup correction per isocenter. RESULTS: Significant variations in favour of HA plans were computed for both target dose indexes, CI (p < .01) and GI (p < .01). The lower GI in HA plans was the likely cause of the significant reduction in V12 to the brain-minus-PTV (p = .023). Although at low doses, below 2-5 Gy, the sparing of the brain-minus-PTV was in favour of RA plans, no significant difference in terms of mean doses to the brain-minus-PTV was observed between the two groups (p = .31). Finally, both MU (p < .01) and OTT (p < .01) were significantly reduced by HyperArc plans. CONCLUSIONS: For linac-based SRS/FSRT of multiple brain lesions, HyperArc plans assured a higher CI and a lower GI than standard multiple-isocenter VMAT plans. This is consistent with the computed reduction in V12 to the brain-minus-PTV. Finally, HyperArc treatments were completed within a typical 20 min. time slot, with a significant time reduction with respect to the expected duration of multiple-isocenters VMAT.
引用
- Ruggieri R, Naccarato S, Mazzola R, et al. Linac-based VMAT radiosurgery for multiple brain lesions: comparison between a conventional multi-isocenter approach and a new dedicated mono-isocenter technique. Radiat Oncol. 2018. PMID: 29506539. doi:10.1186/s13014-018-0985-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。